Cargando…
Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305883/ https://www.ncbi.nlm.nih.gov/pubmed/32593144 http://dx.doi.org/10.1016/j.msard.2020.102315 |
| _version_ | 1783548556463833088 |
|---|---|
| author | Conte, William L |
| author_facet | Conte, William L |
| author_sort | Conte, William L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7305883 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73058832020-06-22 Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia Conte, William L Mult Scler Relat Disord Correspondence Elsevier B.V. 2020-09 2020-06-20 /pmc/articles/PMC7305883/ /pubmed/32593144 http://dx.doi.org/10.1016/j.msard.2020.102315 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Conte, William L Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia |
| title | Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia |
| title_full | Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia |
| title_fullStr | Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia |
| title_full_unstemmed | Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia |
| title_short | Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia |
| title_sort | attenuation of antibody response to sars-cov-2 in a patient on ocrelizumab with hypogammaglobulinemia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305883/ https://www.ncbi.nlm.nih.gov/pubmed/32593144 http://dx.doi.org/10.1016/j.msard.2020.102315 |
| work_keys_str_mv | AT contewilliaml attenuationofantibodyresponsetosarscov2inapatientonocrelizumabwithhypogammaglobulinemia |